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Abstract
The commercial creation and sale of embryos has begun, posing a series of ethical questions that 
have received little scholarly attention. Some of the concerns that arise are similar to those posed 
by the sale of gametes, while other issues differ markedly. Questions emerge, firstly, regarding the 
rights of the unborn children – their ability to know their biological parents. Companies that create 
human embryos de novo may wish to keep gamete providers anonymous. Many of these offspring 
will thus never learn that their parents are not their biological parents. Yet, such disclosures – 
regarding not only one, but both of these biological parents – may be important for these 
individuals; and lack of this knowledge may impede their physical and psychological health. 
Secondly, questions surface regarding the fees that providers should charge for embryos, and 
whether these amounts should vary based on the traits of one or both of the gamete donors. Some 
prospective parents may seek specific traits in a baby (e.g., height or eye/hair coloring), prompting 
creation of embryos from two gamete donors who possess these characteristics. Thirdly, 
ownership of embryos created without an advanced directive by patients poses dilemmas – e.g., 
disposition of any remaining embryos. Fourthly, guidelines do not yet exist to limit the number of 
embryos sold from each pair of gamete donors. Hence, unbeknownst to each other, full siblings 
could potentially meet, get married and procreate. This discussion has several critical implications 
for future practice, and professional education and policy. Patients with diseases associated with 
genetic tests may well ask obstetricians, gynecologists and other physicians about these techniques 
and practices. Clinicians can refer such patients to Assisted Reproductive Technology specialists, 
but familiarity with the basic aspects of the issues and complexities involved could aid themselves 
and their patients Several of these issues can be relatively easily addressed through guidelines 
from professional associations (e.g., limiting the number of embryos sold from each pair of 
gamete donors). As creation and sales of embryos will likely spread, consideration of appropriate 
© 2014 Elsevier Inc. All rights reserved.
Corresponding Author: Robert Klitzman, MD, 1051 Riverside Drive; Mail Unit #15, New York, NY 10032, Office Phone: 
646-774-6912; Alternate Office Phone: 646-774-6913, Office Fax: 646-774-6955, rlk2@columbia.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The authors report no conflict of interest
NIH Public Access
Author Manuscript
Am J Obstet Gynecol. Author manuscript; available in PMC 2016 February 01.
Published in final edited form as:













responses is critical in order to establish standards of care to help the future offspring, and ensure 
ongoing public trust.
Keywords
Ethics; Policy; Professionalism; Assisted Reproductive Technologies (ART); Risks/Benefits
Where life begins
Recently, a California company has begun creating and selling embryos, posing a range of 
ethical questions that have received little scholarly attention. Other clinics may now consider 
doing the same. Strikingly, this new market has received attention in the popular media1, but 
relatively little in the academic literature. Donated cryopreserved embryos can enable 
would-be parents who lack both sperm and eggs to have children, but several critical ethical 
dilemmas emerge. Indeed, only three countries (Russia, India and the United States) permit 
individuals to buy and sell human eggs. But, should we now permit buying and selling 
embryos, too, and if so how? Some individuals and organizations may immediately oppose 
this technology for religious or moral reasons. Some feminists and others have viewed the 
sale of eggs, and presumably embryos, as commodification, arguing that such markets 
cheapen human life.1 But can these procedures be ethically permissible, depending on how 
and for what indicators they are performed? What specific concerns may arise, and could 
guidelines address these?
Cohen and Adashi2 recently concluded that the ethical issues involved in creating embryos 
for donation are essentially no different than those posed by buying and selling human 
sperm or eggs or donating embryos. The only clear difference, they argue, concerns legal 
issues of parentage.
Yet, though some of the issues are similar, others differ markedly. Neither an egg nor a 
sperm, by itself, can become a human being, while an embryo certainly does, and therefore, 
arguably, warrants special consideration. A purchased gamete contains only half of the 
future child’s DNA, whereas the embryo contains the entire genome. Moreover, creating 
embryos raise questions related to quandaries of “when life begins” and when “an individual 
commences”. Some individuals believe that embryos have greater moral standing than do 
gametes. In our pluralistic society, broader ethical debates continue over that issue that we 
cannot resolve here. But that debate does not need to be resolved in order to examine 
particular critical issues that arise regarding embryo sales. Even regarding similar aspects of 
purchasing a gamete versus an embryo, commercial transactions involving embryos raise 
these dilemmas more acutely and forcefully, which should prompt us to revisit, rather than 
ignore these on-going controversies in this new context.
In this paper, we examine arguments pro and con, and suggest ways of potentially 
proceeding. Should embryos be thought of as a commodity, a product that may be bartered 
or sold in the open marketplace, or as something different, and if so, how? Questions arise 
concerning whether guidelines or parameters should be developed, and if so what – e.g., 
regarding anonymity or potential future contact or mandated or permitted exchange of 
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information between offspring and gamete donors; limits in the number of offspring created 
from each batch of procured gametes; and the final dispositions of any embryos above this 
arbitrary number. The World Health Organization states that cells and tissues should be 
donated only without payment – except for reimbursement of reasonable expenses (e.g., loss 
of income) – and without any “advertising the need for or availability of cells…with a view 
to offering or seeking payment…”3 Yet international consensus documents are not always 
followed and do not constitute law; and in the US and several other countries, purchase and 
advertising of gametes regularly occurs.
Physicians from a wide variety of specialties should be aware of issues related to embryo as 
well as gamete donation, as they may well be asked questions regarding these techniques 
and practices. Patients with diseases associated with genetic tests may ask internists, 
obstetricians, pediatricians, psychiatrists and others about whether in the future to screen 
embryos, or purchase others’ gametes or embryos from nonaffected donors, instead of using 
their own. Clinicians can refer such patients to ART specialists, but familiarity with the 
basic aspects of the issues and complexities involved could aid themselves and their 
patients.
Currently, this practice of selling embryos may be relatively limited in scope, but the 
number of providers doing it remains wholly unknown. Even if it may not be widespread 
presently, it will undoubtedly become far more prevalent, as have other new Assisted 
Reproductive Technologies (ARTs). The unique nature of the embryo as an object for sale 
makes the ethical questions raised critical.
Arguably, the different possible indications for embryo donation affect the ethical 
justifications in each case. For couples in which both members lack gametes, the procedure 
may be ethically justifiable, depending on how it is performed. Yet couples who purchase 
embryos to achieve offspring with particular desired non-medical characteristics (e.g., blond 
hair and blue eyes) pose several concerns.
Questions arise, too, concerning the rights of the unborn children – their ability to know 
their biological parents. Presumably, many of these offspring will never learn that their 
biological parents are not their parents. Companies that create human embryos de novo, and 
gamete donors themselves may wish to keep donations anonymous. Currently, many sperm 
or egg recipients do not tell their child that he or she was conceived using someone else’s 
egg or sperm, fearing that the child will love them less. Yet research has suggested that most 
adults conceived using donor sperm want information about their donors, and think it should 
be provided.4 Some offspring inadvertently find out later (e.g., if a relative discloses the 
information, or the offspring discovers medical or legal documents) and may as a result feel 
disturbed, confused, mistrustful and alienated. With a donated embryo, parents may be even 
more reluctant to disclose that donation occurred, since neither of them is biologically 
related to their offspring. Hence, with many cases of embryo donation, no contact will 
probably ever occur between both – not only one – of these biological parents and their 
offspring. Yet, such disclosures may be important for these individuals, who may gain 
knowledge that can aid their physical and psychological health.5,6 Gamete donors may, for 
instance, later discover genetic cancers or other serious familial diseases that would be 
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important and useful information to these offspring. Many predictive genetic markers are 
best interpreted in the context of known family medical history.
Offspring may also want to know from whom they are descended for the knowledge in and 
of itself – to know their “roots”. They may also reflect differently on their own identity if 
they know that they were created from embryos produced by individuals who never met and 
had nothing, knowingly, in common. Moreover, their biological parents each in fact 
provided their gametes for money, and thereby created the offspring partly for monetary 
self-gain, rather than love or altruism alone. Arguably, offspring have a right to know this 
information. One might argue that such disclosures may cause harm. But data from sperm 
donation suggest that the benefits of disclosures outweigh the possible risks.4
Questions arise, too, concerning how much providers or agencies should charge for 
embryos. The American Society of Reproductive Medicine (ASRM) has stated that women 
donating eggs may be compensated for their time and the risk involved. Payment, however, 
should not be for the eggs per se, but for the service rendered, and not tied to the quality of 
eggs. Unfortunately, many donor egg agencies and fertility clinics pay more for eggs from 
women with more perceived desirable pedigrees (e.g., higher SAT scores), and “proven” 
successful past donation.7
Desires of some prospective parents for specific traits in a baby (e.g., height or eye/hair 
coloring) can prompt creation of embryos from two gamete donors who each have these 
traits. Since egg donor compensation has varied based upon desired attributes, the costs of 
embryos may also reflect the desirability of perceived traits. Questions thus emerge of 
whether “bidding” for highly valued embryos should be allowed (with sale to the highest 
bidder, driven by market demand) and embryos deemed less desirable should be 
“discounted”. Wealthy prospective parents may be able to bid competitively for embryos 
from gamete donors more extensively screened for health, beauty, athleticism, intellect, or 
avoidance of various mutations or less desirable traits, widening gaps between the haves and 
the have-nots, potentially fostering inequality and injustice. Future selection for or against 
certain traits (e.g., from obesity or homosexuality) may promote misunderstandings that 
genes “cause” certain traits that instead may result from complex interactions of both nature 
and nurture.
ASRM issues guidelines, but neither systematically monitors nor enforces them, and a 
portion of clinicians fail to follow these recommendations. For instance, ASRM 
recommends that donors be over 21 years of age, but over 40% of clinics appear to target 
younger women, who generally have better quality eggs, but may not have fully considered 
the long-term consequences of donation.8 Nonetheless, these guidelines serve critical roles, 
establishing standards of practice to which many providers commonly appear to adhere. 
ASRM could thus consider issuing additional guidelines that the costs of embryos offered to 
patients should not be linked to perceived desirable qualities.
Ownership of embryos created without an advanced directive by patients pose dilemmas, 
too. What if the creating party, corporate or professional, goes bankrupt – as did the 
Icelandic biobanking company, DecodeGenetics, resulting in ownership of all its genetic 
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data by a British holding company? What if one or both gamete donors change their mind, 
and demand either access to the embryos for their own personal use, or destruction of the 
embryos? They may have signed a contract that defines the nature of their intent at the time 
of donation, but is it enforceable, and if so, in perpetuity? Questions emerge if the 
individuals who purchased the embryos wish to re-sell or donate them to others, or divorces 
after buying, but before using them.
Additionally, unbeknownst to each other, full siblings could potentially meet, get married 
and procreate. Embryo banks may argue that this event is unlikely, since these offspring 
may be born all over the country. But people move, and companies are located in particular 
regions from which they disproportionately obtain patients. Moreover, no guidelines limit 
how many embryos these programs create and sell; and the buyers are not followed over 
time. Egg donor and embryo registries are desirable, but don’t yet exist. Until they do, 
intermarriage, although not very likely, is entirely possible.
Guidelines also do not exist to limit the number of prospective parents who could buy 
embryos from a given pair of gamete donors. Cohen and Adashi argue that concerns about 
potential intermarriage among children born through embryo sales “apply equally” to 
children born from single gamete donors, and can be handled through similar regulations 
and procedures.2 But the situations differ significantly, since offspring from the same sperm 
donor, but different mothers, are half siblings, and share only half their DNA. Offspring 
from the same batch of embryos (i.e., the same egg as well as sperm donors) would be full 
siblings, and can share their entire DNA. The risks of recessive diseases in their offspring 
are thus far higher.
Several of these issues can be relatively easily addressed through guidelines from ASRM 
(e.g. limiting the number of purchasers of embryos from each pair of gamete donors). As 
this practice will likely spread, appropriate guidelines are critical to establish as standards of 
care for the benefit of the future offspring, and to ensure ongoing public trust.
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Table I
Ethical challenges and questions posed by companies making and selling embryos
• Questions about the moral status of the embryo
– Ethical justification may vary with indications for embryo donation (i.e., medical vs non-medical research)
• Rights of unborn child
– Arguably, offspring have a right to know that their parents are not their biological parents and such disclosure would be 
beneficial
– Currently, gamete donors are anonymous, but problems can ensue.
♦ Offspring won’t be able to know either biological parent’s relevant medical or genetic history
– But will the child eventually
♦ Be told that he/she was created from a purchased embryo?
♦ Be able to contact biological parents?
♦ Do the rights of offspring to know their parents outweigh the rights of donors to remain anonymous?
• How much will embryos be?
– Made to order based on traits?
– Companies seek to make embryos with desired traits
– Will certain traits be selected for or against, promoting eugenics?
♦ Could foster inequity and injustice
• How much to charge?: Concerns about commodification
– Should the price of embryos vary with an embryo’s traits?
• Questions of ownership (e.g., if a company goes bankrupt)
• Risks of intermarriage
– Should the number of purchasers of embryos created from a given sperm and egg donor be limited?
♦ If so, what should the maximum be?
– Otherwise, could pose harms to subsequent generations
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